# Solar Foods Oyj > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/solarfoods). ## Overview Solar Foods is a Finnish food technology company built around the Solein protein ingredient, which is produced through a proprietary fermentation-based process rather than conventional agriculture. The business develops, manufactures, and commercializes protein raw materials and related applications for food and nutrition customers, with an international market focus. ## Products & services • Solein protein ingredient for food applications • Health & Performance Nutrition formulations • Product concepts and application development • Protein production technology platform • Factory 02 capacity expansion program - **Solein ingredient** (70%) — Protein raw material sold for use in food and nutrition products. - **Health & Performance Nutrition applications** (15%) — Application-specific concepts and formulations built around Solein. - **Technology development and commercialization** (15%) — Development work tied to production process, organism platform, and scale-up. - Solein protein ingredient for food applications - Health & Performance Nutrition formulations - Product concepts and application development - Protein production technology platform - Factory 02 capacity expansion program ## Customers Solar Foods sells into food and nutrition companies that need a high-protein ingredient with stable supply and a differentiated sustainability profile. The first target market highlighted in the reports is Health & Performance Nutrition, where customers value protein functionality, ingredient consistency, and non-animal sourcing. The company also serves product developers and brands that test Solein in consumer-facing concepts before broader commercialization. - **Health & Performance Nutrition brands** (primary) — Buy Solein for protein-rich nutrition products where functionality and supply stability matter. - **Food manufacturers** (secondary) — Use Solein as an ingredient in broader food applications that need protein enrichment. - **Consumer brands and formulators** (secondary) — Test and launch products using Solein-based concepts to validate market demand. - **Alternative protein buyers** (emerging) — Seek non-animal protein inputs as an alternative to whey and other conventional sources. - Nutrition brands seeking protein ingredients for performance products - Food manufacturers looking for stable, scalable raw materials - Customers replacing or supplementing whey protein supply - Brands targeting non-animal ingredient claims - Product developers testing Solein in new formulations ## Geography Solar Foods is headquartered in Finland, but its commercial ambition is international and the reports explicitly highlight the United States as the first major target market. The company’s production and development footprint is tied to Finland, while future scale-up is linked to Factory 02. Geography matters because the business depends on access to global food customers, cross-border commercialization, and capital-intensive manufacturing capacity. - Finland is the company base and core development location - United States is the first named target market for commercialization - Commercial model is built for international food and nutrition customers - Factory 02 is the planned scale-up manufacturing location - Global market access matters for ingredient adoption and customer reach ## Strategy Solar Foods is focused on turning Solein from a technology platform into a commercial ingredient business, with Health & Performance Nutrition as the initial beachhead market. The company is also preparing for industrial scale-up through Factory 02, while strengthening its go-to-market organization and product application work to support customer adoption. - **Commercialize Solein in Health & Performance Nutrition** (short-term) — This is the first target market and the main route to early revenue generation. - **Expand production capacity through Factory 02** (medium-term) — Scale-up is needed to support larger customer volumes and broader commercialization. - **Strengthen product and application development** (medium-term) — Customer adoption depends on proving functionality in real formulations. - Commercialize Solein in Health & Performance Nutrition - Build customer traction through product concepts and applications - Scale manufacturing through Factory 02 - Strengthen go-to-market and commercial organization - Advance production process and organism platform development ## Risks Solar Foods remains exposed to early-stage commercialization risk, including the possibility that demand ramps more slowly than expected before new capacity comes online. The business also depends on external financing, regulatory and customer adoption in new markets, and successful scale-up of a novel production process. As a food ingredient company, it faces competition from whey, plant-based proteins, and other alternative protein technologies. - **Funding dependence** [critical] — The company needs additional capital, loans, and grants to finance commercialization and capacity build-out. - **Slow commercialization before Factory 02** [high] — Meaningful revenue is expected to depend on future production capacity and customer adoption. - **Technology and scale-up execution** [high] — A novel fermentation-based protein process must work reliably at industrial scale. - **Competitive alternative proteins** [medium] — Customers can choose from whey, plant-based, and other emerging protein sources. - **Macroeconomic and geopolitical uncertainty** [medium] — Global trade disruption, tariffs, and conflict can affect customer demand and planning. - Dependence on external funding to support growth and scale-up - Commercialization may lag until Factory 02 is operational - Novel production process carries scale-up and execution risk - Competition from whey, plant-based, and cell-cultured proteins - Geopolitical and trade uncertainty can affect international markets ## Accounting The most important accounting judgments are development cost capitalization, grant accounting, and impairment risk on capitalized projects. Lease commitments, contingent VAT exposure on property investment, and share-based compensation also affect reported liabilities and equity. Because the company is still scaling, the timing of when development spending is capitalized versus expensed can materially change reported results. - **Capitalized development costs** — Affects intangible assets, operating expense, and future write-down risk - **Government grants** — Reduces net investment and influences reported R&D intensity - **Lease commitments** — Affects lease liabilities, depreciation, and interest expense - **Contingent VAT on property investment** — Could create a future liability if taxable use declines - **Share-based compensation and option dilution** — Affects equity, EPS dilution, and compensation expense - Development costs are capitalized when future benefits are expected - Research costs are expensed as incurred - Grants reduce capitalized investment and development spend - Capitalized development assets may require impairment - Lease commitments and property VAT review create long-dated obligations - Share-based payments and option dilution affect equity --- *Last updated: 2026-08-11T04:04:55.854169+00:00*